Genprex, Inc.

GNPX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016
Operating Activities
Net Income $-3.3M $-4.1M
Depreciation & Amortization — —
Depreciation $3.2K $862
Amortization — —
Stock-Based Compensation $1.3M $2.7M
Net Cash from Operating Activities $-2.2M $-1.2M
Investing Activities
Capital Expenditures $5.9K $5.0K
Business Acquisitions — —
Net Cash from Investing Activities $-63.4K $-89.5K
Financing Activities
Dividends Paid — —
Stock Repurchases — —
Net Cash from Financing Activities $794.0K $2.7M
Net Change in Cash $-1.4M $1.4M
Free Cash Flow $-2.2M $-1.3M
← Newer Page 2 of 2 Older →